[Piroctone olamine disrupts mitochondrial dynamics in glioma cells through the PI3K/AKT pathway]

W Xu1,2, J Ye1,2, F Wang3

  • 1Key Laboratory of Noncoding RNA Transformation Research of Anhui Higher Education Institution, Wannan Medical College, Wuhu 241002, China.

Abstract

Insights

Piroctone olamine (PO) inhibits glioma cell growth and promotes apoptosis by disrupting mitochondrial function via the PI3K/AKT pathway. This study reveals PO as a potential therapeutic agent for glioma treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Context:

  • Glioma is a primary brain tumor with limited treatment options.
  • Understanding the molecular mechanisms of novel therapeutic agents is crucial for developing effective cancer therapies.

Purpose:

  • To investigate the anti-glioma effects of piroctone olamine (PO).
  • To elucidate the underlying molecular mechanisms, focusing on mitochondrial function and the PI3K/AKT pathway.

Summary:

  • Piroctone olamine (PO) significantly inhibited glioma cell proliferation (U251, U373) in a dose- and time-dependent manner.
  • PO induced apoptosis, decreased mitochondrial membrane potential, and altered mitochondrial morphology.
  • PO downregulated the PI3K/AKT pathway, impacting mitochondrial fission and fusion proteins.

Impact:

  • PO demonstrates significant anti-glioma activity, suggesting its potential as a therapeutic agent.
  • The findings provide insights into the mechanism of action of PO, involving mitochondrial dynamics and the PI3K/AKT pathway.
  • This research may pave the way for novel therapeutic strategies targeting glioma.

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K